This article provides a comprehensive overview of the compatibility of Ancef (Cefazolin), a commonly used cephalosporin antibiotic, with Lactated Ringer's (LR) solution, a widely used intravenous fluid for irrigation and drug dilution. Understanding the potential interactions and compatibility of these two substances is crucial for safe and effective clinical practice.
Potential Interactions and Precautions
While initial assessments may not reveal direct interactions between cefazolin and Lactated Ringer's Injection, it is essential to acknowledge that this does not guarantee the absence of interactions. Continuous monitoring and caution are advised.
General Considerations for Antibacterial Therapy
Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with a history of gastrointestinal disease, particularly colitis. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C. difficile, whose toxins A and B contribute to CDAD development.
Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Antibacterial drugs not directed against C. difficile may need to be stopped if CDAD is suspected or confirmed. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefazolin, and may range in severity from mild to life-threatening.
After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an oral antibacterial drug clinically effective against C. difficile.
Read also: Detailed Review of Arccos Golf
Sodium Content and Fluid Retention
Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium-containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.
Parenteral cefazolin sodium contains approximately 46 mg (2 mEq) of sodium per each gram of cefazolin activity.
Impact on Patients with Impaired Glucose Tolerance
LVP solution for peritoneal dialysis contains dextrose and may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation or modification of antidiabetic therapy during treatment with these solutions.
Renal Function and Hemodialysis
Most cephalosporin antibiotics are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis. Most beta-lactam antibacterial agents are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.
The serum concentrations of beta-lactam antibacterial agents and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function. Dosage adjustments may be necessary, and modifications should be based on the degree of renal dysfunction as well as severity of infection in accordance with the individual manufacturer product information.
Read also: Apps for Oura Ring Users
ANCEF may be used in patients with reduced renal function with the following dosage adjustments:
- Patients with a creatinine clearance of 55 mL/min. or greater or a serum creatinine of 1.5 mg % or less can be given full doses.
- Patients with creatinine clearance rates of 35 to 54 mL/min. or serum creatinine of 1.6 to 3.0 mg % can also be given full doses but dosage should be restricted to at least 8 hour intervals.
- Patients with creatinine clearance rates of 11 to 34 mL/min. or serum creatinine of 3.1 to 4.5 mg % should be given 1/2 the usual dose every 12 hours.
- Patients with creatinine clearance rates of 10 mL/min. or less or serum creatinine of 4.6 mg % or greater should be given 1/2 the usual dose every 18 to 24 hours.
Renal Dosing Guidelines:
>55/q6-8h || 35-54/q8h || 11-34/ 50% usual dose q12h || <10 ml/min/ 50% to full dose q24-48h
Neurological Considerations
Cephalosporins have been implicated in triggering seizures. Nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins, particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal dysfunction. Anticonvulsant therapy should be continued in patients with known seizure disorders.
Neurotoxic reactions (e.g., encephalopathy, aphasia, asterixis, myoclonus, seizures, nonconvulsive status epilepticus, coma) have been reported in such patients treated parenterally with these agents. Dosage should be adjusted based on the degree of renal function.
Read also: What is S3-Compatible Storage?
Hepatic Effects
Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.
Hypersensitivity Reactions
BEFORE THERAPY WITH ANCEF IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFAZOLIN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO ANCEF OCCURS, DISCONTINUE TREATMENT WITH THE DRUG.
Pediatric Dosage Adjustments
In pediatric patients, a total daily dosage of 25 to 50 mg per kg (approximately 10 to 20 mg per pound) of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections. Total daily dosage may be increased to 100 mg per kg (45 mg per pound) of body weight for severe infections.
In pediatric patients with mild to moderate renal impairment (creatinine clearance of 70 to 40 mL/min.), 60 percent of the normal daily dose given in equally divided doses every 12 hours should be sufficient. In patients with moderate impairment (creatinine clearance of 40 to 20 mL/min.), 25 percent of the normal daily dose given in equally divided doses every 12 hours should be adequate. Pediatric patients with severe renal impairment (creatinine clearance of 20 to 5 mL/min.) may be given 10 percent of the normal daily dose every 24 hours.
Preparation and Administration
Parenteral drug products should be SHAKEN WELL when reconstituted and inspected visually for particulate matter prior to administration. As with other cephalosporins, reconstituted Cefazolin for Injection, USP tends to darken depending on storage conditions, within the stated recommendations.
When reconstituted or diluted according to the instructions below, ANCEF is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5°C or 41°F).
For IM injection, IV direct (bolus) injection or IV infusion, reconstitute with Sterile Water for Injection according to the following table:
| Route of Administration | Reconstitution Instructions |
|---|---|
| IM Injection | Reconstitute vials with Sterile Water for Injection according to the dilution table above. Shake well until dissolved. ANCEF should be injected into a large muscle mass. |
| IV Direct (Bolus) Injection | Following reconstitution according to the above table, further dilute vials with approximately 5 mL Sterile Water for Injection. |
| IV Infusion | Reconstitute with 50 to 100 mL of Sodium Chloride Injection or other IV solution listed under ADMINISTRATION. When adding diluent to vial, allow air to escape by using a small vent needle or by pumping the syringe. SHAKE WELL. |
Thaw frozen container at room temperature (25°C/ 77°F) or under refrigeration (5°C/41°F). Check for minute leaks by squeezing container firmly. Handle frozen product containers with care.
Y-Site Administration Compatibility Study
A study was conducted to test the compatibility of intravenous (IV) lactated Ringer’s injection (LR) with 94 injectable (IV) drugs during simulated Y-site administration. Lactated Ringer’s injection (LR) is a sterile, nonpyrogenic solution that may be used for intravenous (IV) irrigation, washing, and rinsing and also acts as a diluent for infusion of drugs.
Methods
Ninety-four IV drugs were investigated for compatibility with LR (Baxter). Each sample was prepared in duplicate and performed at room temperature. Two observers performed visual evaluation independently immediately upon mixing and then 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours after admixture. Another observer performed a particle counting test on 1 of the 2 duplicates of each admixture that did not immediately show incompatibility and then after 4 hours by a light obscuration particle count test.
Results
Of the 94 tested drugs, 86 were found to be compatible with LR. A total of 8 drugs were found to be physically incompatible. Of these incompatible drugs, 7 were directly identified visually, and 1 was confirmed by the light obscuration particle count test.
Conclusion
Lactated Ringer’s injection was physically compatible for 4 hours with 86 tested drugs during simulated Y-site administration.
Antimicrobial Spectrum
In vitro tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell wall synthesis.
ANCEF is effective against:
- S. aureus (including ß-lactamase-producing strains) and S. epidermidis
- S. pneumoniae
- E. coli, various strains of streptococci, P. mirabilis, and S. pneumoniae, S. aureus (including ß-lactamase-producing strains), P. mirabilis, E. coli
Most strains of indole positive Proteus (Proteus vulgaris), Enterobacter spp., Morganella morganii, Providencia rettgeri, Serratia spp., and Pseudomonas spp.
Prophylactic Use
The prophylactic administration of ANCEF should usually be discontinued within a 24-hour period after the surgical procedure.
Reducing Drug-Resistant Bacteria
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ANCEF and other antibacterial drugs, ANCEF should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
Alaris Pump Introduction with Primary and Secondary IV Infusion Programming
tags: #is #ancef #compatible #with #lr